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Background: The functional role of dietary carbohydrates in nutrition is one of the most complex and at times controversial areas
in nutritional science. In-vitro and in-vivo studies suggest that certain dietary saccharide biopolymers can have bifidogenic and or
immunomodulatory effects, and that some could represent preferential substrates or precursors that can impact cellular glycosylation.
Objective: Examine the impact of oral ingestion of a standardized dietary plant-derived polydisperse polysaccharide supplement
(Advanced Ambrotose powder (AA)) on the N-glycosylation status of serum glycoproteins in a cohort of healthy individuals.
Design: An open-label study was carried out. This study was in two phases: pilot study (n¼6 individuals) to assess safety and
dose, and a larger study (n¼12) to evaluate specific glycosylation changes. Serum N-glycosylation profiles, using mass
spectrometry, were monitored at weekly intervals, for 7 weeks, to evaluate baseline levels and normal fluctuations. The
individuals were then monitored for a further 7 weeks, during which time increasing doses of AA were ingested (1.3–5.2g/day).
Results: No adverse events were encountered. AA supplementation resulted in distinct changes in the relative intensities of
seven biantennary N-glycans (Po0.001), and a significant overall shift towards increased sialylation. Regression analysis revealed
a dose-dependent decrease in mono- and di-galactosylated structures (coefficient  0.130 decrease/week: P¼0.02 and  0.690:
P¼0.005), and a concomitant increase in disialylated glycans ( 1.083: Po0.05).
Conclusions: Supplementation with the dietary plant-derived polysaccharides in AA resulted in significant changes in serum
protein N-glycosylation in healthy individuals. How this occurs and whether it has biological significance remains to be evaluated.
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Introduction
Fueled by the current interest in the link between diet and
health (Ma et al., 2008; Estruch et al., 2009; Lomax and
Calder, 2009; Schiffrin et al., 2010), there is now a surge of
research by various groups into the biological activities and
potential beneficial effects of dietary saccharide biopolymers
(Schepetkin and Quinn, 2006; Cumashi et al., 2007; Vos
et al., 2007; Rideout et al., 2008; Weickert and Pfeiffer, 2008;
Bruzzese et al., 2009; Chan et al., 2009; Courtois, 2009; Graff
et al., 2009; Jacobs et al., 2009; Liu et al., 2009). These
biopolymers represent a broad range of structurally diverse
(Schepetkin and Quinn, 2006), non- or low-digestible,
dietary soluble fibers that have been derived from different
species of flora including higher plants, fungi, lichens and
algae, and have been demonstrated (in-vitro or in-vivo)t o
affect beneficially one or more target cellular or body
functions (Cumashi et al., 2007; Ho et al., 2007; Hua et al.,
2007; Vos et al., 2007; Kim and Joo, 2008; Ma et al., 2008;
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et al., 2009; Lomax and Calder, 2009; van den Heuvel et al.,
2009).
The physiological effects attributed to these ‘functional’
polysaccharides can be divided into six main categories:
(1) beneficial effects on colonic microflora (Jacobs et al.,
2009) and gastrointestinal physiology; that is functioning as
a prebiotic (Macfarlane et al., 2008; de Vrese and Schrezenmeir,
2008; Lomax and Calder, 2009); (2) immunomodulatory
effects (Leung et al., 2006; Schepetkin and Quinn, 2006;
Cumashi et al., 2007; Hua et al., 2007; Vos et al., 2007;
Benyacoub et al., 2008; Kim and Joo, 2008; Bruzzese et al.,
2009; Burrows et al., 2009; Graff et al., 2009; Mizuno et al.,
2009); (3) anti-angiogenetic (Cumashi et al., 2007) and anti-
tumor effects (Chan et al., 2009; Liu et al., 2009); (4) altered
lipid metabolism (Rideout et al., 2008; Chen and Huang,
2009); (5) improved bioavailability of essential minerals
(Bo et al., 2006; van den Heuvel et al., 2009); and (6) other
beneficial health effects such as enhanced production of
growth factors involved in re-epithelization and wound
healing (Jettanacheawchankit et al., 2009).
In this respect, many of the dietary saccharide
polymers studied (isolated from 435 species) (Schepetkin
and Quinn, 2006), exhibiting multifunctional physico-
chemical and physiological characteristics, are now being
redefined as secondary metabolites (Vos et al., 2007;
Macfarlane et al., 2008; Weickert and Pfeiffer, 2008; Courtois,
2009), or biological response modifiers (BRMs) (Leung et al.,
2006).
These BRM polysaccharides (Table 1) have diverse struc-
tural complexity, and belong to a wide range of low or high
molecular weights, soluble or insoluble, acidic or neutral,
homo- or hetero-polymers, which may or may not undergo
varying degrees of degradation in the digestive tract either by
bacterial enzymes or by specific conditions associated with
the digestive process (Sinnott et al., 2007; Macfarlane et al.,
2008; van den Broek et al., 2008; Arasaradnam et al., 2009;
Courtois, 2009; Jacobs et al., 2009; Schiffrin et al., 2010).
Recent evidence suggests that the potential for these
polysaccharides to undergo some degree of degradation is
highly dependent on the metabolic potential encoded by the
combined genomes of the gut microbiota (Arasaradnam
et al., 2009; Tuohy et al., 2009).
Current studies into the link between the bioconversion of
these dietary polysaccharides, their bioavailability and their
downstream effects on the host metabolism and physiology
are using metabolomics and metagenomics approaches
(Jacobs et al., 2009). These and other innovative approaches
in the field of colonic fermentation (Chassard et al., 2007;
Arasaradnam et al., 2009) are providing novel insights into
gut microbial–human mutualism (Possemiers et al., 2009), its
impact on regulating human health and disease, and the
importance of dietary modulation (Leung et al., 2006;
Macfarlane et al., 2008; Bruzzese et al., 2009; Liu et al.,
2009; Lomax and Calder, 2009; Tuohy et al., 2009; Schiffrin
et al., 2010).
Although many of the physiological traits attributed to
dietary polysaccharides may be secondary, that is, related to
Table 1 Examples of dietary polysaccharides that have been studied in relation to their biological activities
Dietary polysaccharides Features/examples Biological functions
Sulfated polysaccharides;
glycosaminoglycans
Heparin-like fucoidans—
obtained from edible seaweed.
Potent antioxidant and anticoagulant properties, as well as
immunopharmacological properties such as anti-inflammatory
activity (Cumashi et al., 2007; Kim and Joo, 2008; Mizuno et al., 2009).
Glucomannan polysaccharides Acemannan—obtained
from Aloe vera.
Potent immunostimmulants (Leung et al., 2006) that also exhibit
anti-tumor and wound-healing properties via induction of fibroblast
proliferation and increased type I collagen expression (Leung et al.,
2006; Jettanacheawchankit et al., 2009).
b-glucans; wide-spread
homo-polysaccharides
(D-glucose monomers linked
by glycosidic bonds) with
different molecular weights
and degree of branching.
They occur most commonly
as the cell wall of yeast,
certain fungi and mushrooms
(e.g. lentinan).
These exhibit marked anti-tumor (Chan et al., 2009; Liu et al., 2009)
and immunostimulatory (Mizuno et al., 2009) activity, affecting both
the innate, as well as the adaptive arm (Th1 and Th2) of the immune
response (Dalmo and Bogwald, 2008), and may be effective in controlling
blood lipids (Chen and Huang, 2009). Generally insoluble (1,3/1,6)
b-glucan, has greater biological activity than the soluble (1,3/1,4) b-glucans.
Inulin polysaccharides; fructans Fructose polymers±terminal
glucose. Found in many types
of plants. Foods naturally high
in inulin include garlic, onion
and chicory.
These are associated with immunomodulatory anti-inflammatory effects
as well as selective mineral absorption. They have also been implicated
in controlling blood lipids (Bruzzese et al., 2009; Courtois, 2009; van den
Heuvel et al., 2009).
Arabinogalactan polysaccharides Consisting of arabinose and
galactose. Major constituents
of many gums, including gum
gutti and gum tragacanth.
A number of these exhibit immunomodulatory effects via induction of
both pro- and anti-inflammatory cytokines (Schepetkin and Quinn, 2006),
and have been shown to exhibit potent complement-fixing activity and
beneficial prebiotic properties, particularly in gastrointestinal functional
disorders such as Irritable bowel syndrome, by increasing the colonic
contents of short-chain fatty acids. Guar gum has also been implicated
in improving blood lipids (Rideout et al., 2008).
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activities (Schiffrin et al., 2010), evidence from various
pharmacodynamic and pharmacokinetic studies also indi-
cate microflora-independent immunomodulatory effects
(Schepetkin and Quinn, 2006; Ho et al., 2007; Hua et al.,
2007).
This ‘direct’ immunomodulatory effect is instigated by
the binding of certain BRM polysaccharides (for example,
b-glucans) (Dalmo and Bogwald, 2008) to specific receptors
on immune cells in the gut-associated lymphoid tissues, and
results in the intracellular activation of signal transducers
and transcription factors that are associated with various
effector functions of the immune response (Vetvicka et al.,
1996; Schepetkin and Quinn, 2006; Ho et al., 2007; Hua
et al., 2007; Vos et al., 2007; Paur et al., 2008; Burrows et al.,
2009; Graff et al., 2009; Mizuno et al., 2009).
Although the potential mechanisms of the interaction and
the subsequent signal transduction pathways are not fully
understood, the evidence supports the direct binding of BRM
polysaccharides (or their fragments) to pattern recognition
receptors. These receptors are key players in the immune
response (receptors for recognition of microbial polysacchar-
ides) and include toll-like receptors (Leung et al., 2006; Hua
et al., 2007; Dalmo and Bogwald, 2008; Graff et al., 2009),
non-toll pattern recognition receptors (for example, b-glucan
receptor or dectin-1), complement receptor type 3 and
certain transmembrane lectins (Vetvicka et al., 1996; Vos
et al., 2007; Gunning et al., 2009). Recognition by these
pattern recognition receptors can result in intracellular
signaling cascades for example, activation of protein kinases
or nuclear transcription factor kappa B. This can in turn
result in subsequent activation or inactivation of a wide
spectrum of target genes involved in the regulation of a
variety of cellular responses, such as expression of various
cell-surface receptors (Kim and Joo, 2008) and cytokine
production (Leung et al., 2006; Schepetkin and Quinn, 2006;
Cumashi et al., 2007; Dalmo and Bogwald, 2008; Paur et al.,
2008; Jettanacheawchankit et al., 2009).
One of the primary immunomodulatory effects of BRM
polysaccharides is to promote or alter various leukocyte
activities, in particular those of macrophages (Leung et al.,
2006; Schepetkin and Quinn, 2006) and immune-regulatory
Gamma delta T cells (a sub-population of intraepithelial
lymphocytes in the gastrointestinal tract) (Graff et al., 2009),
via changes in cytokine expression (Yoshino et al., 2000; Hua
et al., 2007; Benyacoub et al., 2008; Kim and Joo, 2008;
Burrows et al., 2009; Schiffrin et al., 2010). This in turn can
impact both the innate and adaptive arms of the immune
response and thus result in activation or dampening of these
responses (Schepetkin and Quinn, 2006; Cumashi et al.,
2007; Ho et al., 2007; Vos et al., 2007; Graff et al., 2009;
Mizuno et al., 2009).
Dietary polysaccharide induced immunomodulatory ac-
tivities of note include: increased macrophage cytotoxic and
phagocytic activities, altered pro- and anti-inflammatory
(Leung et al., 2006; Schepetkin and Quinn, 2006; Ho et al.,
2007; Benyacoub et al., 2008; Kim and Joo, 2008; Mizuno
et al., 2009; Schiffrin et al., 2010) and Th1-Th2 balance
(Yoshino et al., 2000; Vos et al., 2007; Burrows et al., 2009), as
well as altered expression of certain adhesion molecules
(Yoshino et al., 2000; Schepetkin and Quinn, 2006; Cumashi
et al., 2007; Ho et al., 2007; Graff et al., 2009). All of which
supports the notion that certain dietary plant polysacchar-
ides may have significant immunomodulatory potential
(Schepetkin and Quinn, 2006; Cumashi et al., 2007; Ho et al.,
2007; Benyacoub et al., 2008; Burrows et al., 2009; Trinchero
et al., 2009; Tuohy et al., 2009).
In view of this and given the important link between
changes in the immune response and the glycosylation of
various effector glycoproteins (Alavi and Axford, 2008), the
aim of this study was to examine the possible affects, if any,
that oral administration of dietary plant polysaccharides
may have on the glycosylation status of serum glycoproteins
in a cohort of healthy subjects. We chose a commercial,
mixed saccharide dietary supplement (AA), the constituents
of which have previously been shown to exhibit prebiotic
(Sinnott et al., 2007), as well as possible immunomodulatory
activities (Lefkowitz et al., 2000; Koetzner et al., 2010), and
for the purposes of this study have no known reported
toxicity or negative side effects associated with their use in
human subjects (Stancil and Hicks, 2009).
Using AA we carried out an open-label dosing study to first
evaluate safety of increased doses, and second to monitor the
affect on the N-glycosylation status of serum glycoproteins
in healthy subjects.
Materials and methods
Study cohort
Healthy volunteers were recruited from the staff at St George’s
University of London. The study design was approved by
the Ethics Committee and volunteers gave written informed
consent.
Supplement
The supplement was Advanced Ambrotose (AA) powder
(provided by Mannatech, Inc., Dallas, TX, USA). AA is a
plant-derived dietary supplement that contains a standar-
dized mixture of partially purified polydisperse saccharide
biopolymers: aloe vera gel powder (containing glucoman-
nan-based polysaccharides), arabinogalactan (high-M.wt
soluble arabinose and galactose-containing dietary fiber),
gum ghatti and gum tragacanth (mainly soluble mixture of
complex galactose polymers; with other saccharide consti-
tuents including arabinose, rhamnose, fucose, glucose,
mannose, xylose and uronic acids), glucosamine (plant-
derived supplemental glucosamine HCl), Undaria pinnatifida
fucoidans (sulfated fucose polymer that contains other
monosaccharides, galactose and mannose, derived from
edible brown seaweed) and rice starch.
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An open-label dosing study was set up. The study was carried
out in two phases.
Phase 1. Pilot study was carried out to establish safety and
dose necessary to impact serum N-glycosylation profiles. Six
individuals (age range 28–55; 3 females), ingested increasing
doses of AA supplement (increased by 1.3g/week) for 7 weeks
(starting with 1.3g/day for week 1, and reaching 9.1g/day at
week 7). From week 7 to week 11, the group was divided into
two arms; three stopped their supplement while the other
three volunteers continued with supplementation at increas-
ing doses (reaching 14.3g/day by week 11).
Phase 2. A larger study was performed to evaluate glycosy-
lation changes pre- and during-supplementation. A total of
12 volunteers (age range 22–40; 6 females), were followed for
16 weeks. The first 7 weeks, designated as the pre-supple-
mentation period (week  7 to 0), was to establish baseline
serum N-glycosylation patterns and normal fluctuations.
Following this period, the individuals ingested increasing
doses of AA supplement (week 1–4 at 1.3g/day; week 5–6 at
2.6g/day and week 7–8 at 5.2g/day). This was followed by a
final week with no supplement intake (week 9).
Sample collection
Serum was extracted from blood samples and stored at
 401C. Samples were tested in a blind manner. The codes
were not revealed until the study was completed.
Glycosylation analysis
Serum (40ml) glycoproteins were deglycosylated using a Peptide
N-Glycosidase-F (New England BioLabs Inc., Hitchin, Herts, UK)
according to the manufacturer’s instructions. Released N-glycans
were isolated by C18 (Supelco, Poole, Dorset, UK), and
graphitized carbon columns, freeze-dried, reconstituted in
100ml of deionised water, ready for Glycan profiling by Matrix
assisted laser desorption ionisation time-of-flight mass spectro-
metry (MS; Kratos Analytical, Ltd., Manchester, UK), set in
positive linear mode and calibrated with a dextran ladder.
Dihydroxy-benzoic acid was used as the matrix.
Statistical analysis
Where necessary the data were log transformed. To allow
for time trends analysis of covariance with time as a
continuous predictor and subject as a categorical factor
was used. For each glycan structure, two regression models
were fitted. The first ignored AA and fitted a straight-
line relationship with time. The second allowed for
different regression lines in the pre-supplement and supple-
ment periods. These two models were compared using an
F test. The difference between the sums of squares was
calculated. The ratio of this to the residual mean square
for the larger, two period model¼F ratio; used to test effect
of AA.
Correction for multiple comparisons. The Bonferroni method
was applied and significance was set at Pp0.006.
Dose-effect
Only the data following the start of AA were used to analyse
regression of each glycan on dose and subject as a categorical
factor. Time was included as a second covariate (to allow for
possible time trends); such that if there was a significant dose
trend even after adjustment for time, the effect of dose was
fairly secure.
Results
Safety and compliance
Phase 1. All six subjects completed the trial. AA was well
tolerated even at high doses, with no adverse reactions.
Phase 2. All six male and five female volunteers completed
the trial. However, because of palatability issues at high
doses, four of five female volunteers stopped supplementa-
tion earlier than planned; two at week 6 and two at week 7.
One female volunteer withdrew at week 1 (because of
palatability issues), and had data for pre-AA phase only,
and was therefore omitted from the analysis.
Serum N-glycan analysis
Serum N-glycan profiles for each individual at weekly
intervals were examined. Eight main biantennary serum
glycoprotein-derived N-glycan structures corresponding to
different m/z values were identified (Figure 1). Peak inten-
sities were analyzed.
Phase 1. Analysis of the data from the pilot study demon-
strated changes in the serum N-glycan profile in response to
increasing doses of AA supplementation. Example of the
observed changes for each of the six volunteers, at four time
points, for four of the glycans, agalactosylated (G0), mono-
galactosylated (G1), G1fucosylated (G1F) and disialylated (A2),
are shown (Figure 2). The time points chosen were time¼0
(representing baseline values), time¼1 (demonstrating that
changes in serum protein glycosylation were evident within
1 week of supplementation at 1.3g/day;), time¼7 (9.1g/day;
time point at which the group were subdivided into two
arms; three individuals continued with their oral supple-
mentation at increasing doses, whereas the remaining three
discontinued their supplementation) and time¼11 (the end
of the study demonstrating possible differences between the
serum glycosylation profile of the individuals who contin-
ued compared with those that discontinued with their
AA supplementation).
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shown), showed some degree of change in response to AA
supplementation.
Week 7–11: comparisons of the glycan profiles in the three
individuals that discontinued with those that continued AA
supplementation showed differences. These differences were
confined mainly to the neutral glycans (G0F, G1, G1F,
digalactosylated (G2) and G2F) and were particularly notice-
able for G1F, the levels of which reverted (increased) towards
baseline (week¼0) when AA was discontinued (Figure 2).
Figure 1 Schematic diagram of the serum protein-derived biantennary N-linked glycan structures that were analyzed by MS. Eight main
biantennary serum glycoprotein-derived N-glycan structures were identified. These comprised six neutral and two acidic (sialylated) glycans.
The glycans are designated as G0, G1 and G2, according to the number of terminal galactose residues, and monosialylated and or A2,
according to the number of terminal sialic acid residues that decorate the core pentasaccharide (GlcNAc2, Man3). Three of the glycans are F;
giving rise to G0F, G1F and G2F structures. Monosialylation and monogalactosylation may occur on either the a1–3 or a 1–6 arm of the
biantennary structures.
Figure 2 Results from the pilot study; examining possible changes in serum protein N-glycosylation in response to different doses of AA.
The MS percentage intensity for G0, G1, G1F and A2, for each of the six volunteers, at four time points is shown. Week 0 (baseline), week1
(AA at 1.3g/day), week 7 (AA at 9.1g/day) and week 11 (n¼3 continued to take increasing doses of AA, reaching a final dose of 14.3g/day,
represented by the solid line; and n¼3 discontinued their AA supplementation, represented by dashed line, respectively).
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serum protein glycan profiles allowed us to evaluate and
monitor normal glycosylation fluctuations and to establish
statistically meaningful baseline levels. Comparison of the
glycan profiles during the supplementation period with the
time trends observed during the pre-supplementation period
detected distinct changes in the relative intensities of seven
of eight glycans studied. These changes were particularly
striking within the first 1–2 weeks of supplementation
(Figure 3). G0 was the exception, showing major fluctuations
in the pre- as well as supplementation period.
Analysis of covariance using the two regression model was
used to assess the strength of evidence that serum glycosyla-
tion changes followed AA supplementation. A graphical
example of the model as applied to the analysis of the data
for G2 glycans is given (Figure 4). Using this analysis, AA
supplementation was found to result in significant changes
in the levels of all the serum protein-derived N-linked
glycans (G0F, G1, G1F, G2, G2F, monosialylated and A2;
Po0.001) except G0 (P¼0.2).
Dose effect
Regression analysis (with time as a second covariate)
following the start of AA was used to assess the strength of
evidence that change did occur following supplementation
with AA and to examine the effect of dose. The results
(Table 2) show dose effects for G1 and G2; the levels of which
decreased significantly with increasing AA dose (coefficient
factor by which mean glycan levels are multiplied/week
 0.130 and  0.690; P¼0.02 and 0.005, respectively), and for
A2; the levels of which increased significantly with increas-
ing AA dose (Coefficient factor ¼1.083; P¼0.005).
Discussion
Our study reports novel findings showing that the inges-
tion of a standardized mixture of plant-derived polysacchar-
ides can induce significant changes in the N-glycosylation
status of serum glycoproteins in normal healthy individuals.
AA supplementation caused an overall, dose dependent,
shift towards increased sialylation, resulting in significantly
Figure 3 Serum protein N-glycan profiles before and after oral AA supplementation. Plots of MS observations for all subjects for whom there
were measurements made before and during AA supplementation, demonstrating the changes in the eight serum protein-derived biantennary
N-glycans in response to oral AA supplementation (zero time is the last pre-AA measurement). The changes were significant (F test for the effect
of AA; Po0.001) for all the serum protein N-glycans except G0.
Figure 4 Example of the two regression model used for the analysis
of covariance showing the change in serum protein G2 glycan levels
following AA supplementation (Po0.001). For each glycan structure,
two regression models were fitted. The first ignored AA and fitted a
straight-line (solid blue line) relationship with time. The second
allowed for different regression lines in the pre-supplement and
supplement phase (solid black lines; coefficient  0.501 and 0.018,
respectively). This was achieved by creating two time variables; the
first is time up to AA, but is equal to zero afterwards. The second
time variable is time after AA, but is equal to zero before AA.
Dietary plant-derived polysaccharide supplement
A Alavi et al
653
European Journal of Clinical Nutritionlower levels of neutral glycans (G1 and G2:  0.130 and
 0.690 per week, respectively), and increased levels of
fully processed, sialylated, glycans (A2: by a factor of 1.083
per week).
Given that glycosylation is a key post-translational
modification that can significantly affect the overall bio-
physical and biochemical functions of proteins (Alavi
and Axford, 2008; Biol-N0garagba and Louisot, 2003), the
observed shift in the N-glycosylation status of serum
glycoproteins in response to AA supplementation may be
significant and could reflect changes in one or more
physiological parameters.
Interpretation of the biological significance of the ob-
served shift towards more silaylated serum glycoproteins is
complex (Alavi and Axford, 2008) and requires further more
detailed structure-function examination of given serum
glycoproteins (for example, IgG). However, what is known
is that increased levels of sialic acid can affect absorption,
serum half-life and clearance from the serum, as well as the
physical, chemical and immunogenic properties of various
key serum glycoproteins (Alavi and Axford, 2008; Bork et al.,
2009; Schauer, 2009).
Indeed, sialylation changes can have a key role in many
aspects of the immune response, in particular in relation to
the regulation of inflammatory processes, as in the case of
IgG, where sialylation has been shown to function as a
‘switch’. The presence of sialylation is associated with the
steady state, normal, anti-inflammatory function of IgG,
whereas its absence is associated with the pro-inflammatory
effector function (Alavi and Axford, 2008; Anthony et al.,
2008).
However, with this in mind, it is important to note that
the elucidation of a specific physiological role for a given
glycan modification, such as sialylation, poses formidable
challenge. The presence or absence of a particular sugar
residue, at a particular glycosylation site on a given protein,
may have different roles in different biological settings.
In the case of sialic acid, this is further complicated by the
fact that sialylation is linkage-specific, and that the presence
of the different forms of sialic acid may give rise to very
different biological scenarios (Alavi and Axford, 2008;
Schauer, 2009). Further research is therefore needed to more
clearly elucidate specific effects and their consequent
biological significance.
Although the question of whether these serum glycosyla-
tion changes are directly linked to the constituents of AA
per se, or the affect of these on gut microflora (Sinnott et al.,
2007) requires further investigation, the novel finding that
small amounts of a polydisperse mixture of dietary poly-
saccharides can alter the glycosylation of serum proteins is
unexpected and intriguing. This is especially true as it
provides a potential mechanism through which dietary
polysaccharides may alter the effector functions of circulat-
ing molecules. This notion is particularly relevant when
one considers the fact that, time and again, cross-sectional
(Bo et al., 2006) and longitudinal (Estruch et al., 2009) studies
indicate an association between dietary-fiber intake and
levels of inflammatory serum markers (for example, an
inverse correlation with interleukin-6 and tumor necrosis
factor-a receptor-2) (Ma et al., 2008). Continued efficacy
studies using randomized placebo-controlled trials examin-
ing AA and its specific components are warranted to evaluate
possible effect(s).
In conclusion, we have demonstrated that supplementa-
tion with dietary plant polysaccharides in AA can result in
significant serum protein glycomodifications in normal
healthy individuals. These finding are interesting and merit
further research, where it is hoped that an integrative
approach using glycomics together with other—omics such
as metabolomics and metagenomics, focusing on the gut
associated microbe–host mutualism and its impact on
physiology, can help unravel the exogenous and endogenous
effects of dietary components and hence, generate novel
hypotheses for innovative dietary interventions that may
impact health.
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Table 2 Effect of increasing dose of AA supplement on serum protein
N-glycosylation
Glycans Dose alone Dose adjusted for time
Coefficient P-value Coefficient P-value
G0
a 1.124 0.1 0.993 0.09
G0F
a 0.996 0.9 1.020 0.6
G1
b  0.133 0.001  0.130 0.02
G1F
a 0.962 0.3 1.016 0.7
G2
b  0.976 o0.001  0.690 0.005
G2F
b  0.226 0.001  0.170 0.2
A1
b 0.532 0.007 0.669 0.1
A2
a 1.082 0.002 1.083 0.005
Abbreviations: AA, Advanced Ambrotose powder; A1, monosialylated;
A2, disialylated; F, fucosylated; G0, agalactosylated; G1, monogalactosylated;
G2, digalactosylated.
For the purposes of statistical analysis, log transformation was applied to
those glycans that exhibited a skewed distribution (more variable at high
levels than at low levels).
Regression analysis of the data demonstrates significant dose effects for
G1, G2 and A2 serum protein N-glycans.
aAnalysed on logarithmic scale; coefficient¼factor by which mean sugar is
multiplied per week.
bAnalysed on natural scale; coefficient¼increase in mean sugar per week.
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